|
Federal
Register Notices > Notice
of Application >
Orasure Technologies, Inc
FR Doc E7-2320 [Federal Register: February 12, 2007 (Volume 72, Number 28)]
[Notices] [Page 6579-6580] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr12fe07-101]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations
(CFR),
this is notice that on December 12, 2006, Orasure Technologies, Inc., Lehigh
University, Seeley G Mudd-Building 6, 220 East First Street, Bethlehem,
Pennsylvania 18015, made application by renewal to the Drug Enforcement
Administration (DEA) as a bulk manufacturer of the basic classes of controlled
substances listed in schedule I and II:
|
Drug
|
Schedule
|
|
Lysergic acid diethylamide (LSD) (7315)
|
I
|
|
4-Methoxyamphetamine (7411)
|
I
|
|
Normorphine (9313)
|
I
|
|
Tetrahydrocannabinols (THC) (7370)
|
I
|
|
Alphamethadol (9605)
|
I
|
|
Amphetamine (1100)
|
II
|
|
Methamphetamine (1105)
|
II
|
|
Cocaine (9041)
|
II
|
|
Hydromorphone (9150)
|
II
|
|
Benzoylecgonine (9180)
|
II
|
|
Hydrocodone (9193)
|
II
|
|
Morphine (9300)
|
II
|
|
Oxycodone (9143)
|
II
|
|
Meperidine (9230)
|
II
|
|
Methadone (9250)
|
II
|
|
Oxymorphone (9652)
|
II
|
The company plans to manufacture the listed controlled substances in bulk to
manufacture controlled substance derivatives. These derivatives will be used in
diagnostic products created specifically for internal use only.
Any other such applicant and any person who is presently registered with DEA
to manufacture such a substance may file comments or objections to the issuance
of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections being sent via regular mail should be
addressed, in quintuplicate, to the Deputy Assistant Administrator,
[[Page 6580]]
Office of Diversion Control, Drug Enforcement Administration, Washington, DC
20537, Attention: DEA Federal Register Representative/ ODL; or any being sent
via express mail should be sent to DEA Headquarters, Attention: DEA Federal
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia
22301; and must be filed no later than April 13, 2007.
Dated: February 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration.
[FR Doc. E7-2320 Filed 2-9-07; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|
